[go: up one dir, main page]

WO2010104309A9 - Compositions pour prévenir ou améliorer des maladies gastro-intestinales - Google Patents

Compositions pour prévenir ou améliorer des maladies gastro-intestinales Download PDF

Info

Publication number
WO2010104309A9
WO2010104309A9 PCT/KR2010/001450 KR2010001450W WO2010104309A9 WO 2010104309 A9 WO2010104309 A9 WO 2010104309A9 KR 2010001450 W KR2010001450 W KR 2010001450W WO 2010104309 A9 WO2010104309 A9 WO 2010104309A9
Authority
WO
WIPO (PCT)
Prior art keywords
gastric
composition
extract
licorice
ulcer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2010/001450
Other languages
English (en)
Korean (ko)
Other versions
WO2010104309A3 (fr
WO2010104309A2 (fr
Inventor
조일환
권오억
안태군
박지혜
정영미
최낙현
성보현
김영률
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SCIGREEN
CJ CheilJedang Corp
Original Assignee
SCIGREEN
CJ CheilJedang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SCIGREEN, CJ CheilJedang Corp filed Critical SCIGREEN
Priority to CN2010800139052A priority Critical patent/CN102365091A/zh
Priority to RU2011141504/15A priority patent/RU2500416C2/ru
Priority to BRPI1009105A priority patent/BRPI1009105A2/pt
Publication of WO2010104309A2 publication Critical patent/WO2010104309A2/fr
Publication of WO2010104309A3 publication Critical patent/WO2010104309A3/fr
Publication of WO2010104309A9 publication Critical patent/WO2010104309A9/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/233—Bupleurum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/718—Coptis (goldthread)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/32—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the digestive tract

Definitions

  • the present invention relates to a composition for the prevention or treatment of gastrointestinal diseases, and more particularly, to a composition for the prevention or treatment of gastrointestinal diseases, the effect of which is significantly improved by including a combination of herbal ingredients known to be effective in the treatment of conventional gastrointestinal diseases. will be.
  • Inflammation with erosion, redness, bleeding, and edema occurs when gastric acid secretion is increased or gastric mucosal protective layer is damaged by various factors, and this inflammatory lesion is limited to the gastric mucosa. It is called gastric ulcer when it is severely damaged and penetrates the gastric mucosa and damages the submucosal tissue and muscle layer.
  • the duodenum which is directly connected to the stomach, may cause inflammation and duodenal ulcer by similar factors, and gastric ulcer and duodenal ulcer are collectively referred to as peptic ulcer.
  • gastric ulcer drugs have been developed and used as inhibitors and enhancers of defense factors.
  • Representative attack factors include gastric acid, pepsin, alcohol and smoking, stress and nonsteroidal anti-inflammatory drugs, infections of Helicobacter pylori ( Helicobacter pylori ).
  • Factors that weaken the defensive factors include loss of structure and form of the gastric mucosa, decreased mucus secretion, decreased bicarbonate secretion, and decreased prostaglandin production.
  • gastric acid secretion In order to treat inflammation and ulcer of stomach and duodenum caused by attack factors, gastric acid secretion, mucous secretion promotion, gastric mucosal epithelial cell regeneration, inhibition of Helicobacter pylori proliferation and administration of anti-inflammatory drugs are required.
  • the most representative agents for the treatment of gastritis and gastric ulcers are drugs such as antacid, H2-receptor antagonist (H2-RA), proton pump inhibitor (PPI) and gastric mucosa protector for acid secretion.
  • H2-RA H2-receptor antagonist
  • PPI proton pump inhibitor
  • gastric mucosa protector for acid secretion A combination of these drugs and antibiotics is being used to eliminate Helicobacter pylori.
  • these gastric acid secretion inhibitors have a high recurrence rate after the end of the drug administration [Drug Intell. Clin.
  • Gastric mucosal protection agents are known to regenerate mucosal tissue to a similar level as normal to compensate for the shortcomings of these fast-acting gastric acid secretion inhibitors (Folia Pharmacol. Japan, 92: 389, 1988) and are an important part of the treatment of gastritis. .
  • gastric mucosa protective agents have the disadvantage that they are fast-acting, high-dose, and have to be taken for a relatively long time.
  • Korean Patent Laid-Open Publication No. 1996-0021054 discloses a composition for treating gastrointestinal diseases comprising mugwort leaf extract as an active ingredient, and the composition for treating gastrointestinal diseases is commercialized as styrene tablets and sold and prescribed as a successful natural gastritis treatment.
  • Coptis Rhizoma is a rhizome ( Coptis japonica ), a perennial herb of Ranunculaceae, and a rhizome that almost eliminates the roots of the same plants (9 Korean Revisions, 2007). Dry it in the sun and remove the cork layer.
  • the main pharmacological action of Huangshan is known as anti-inflammatory, anti-ulcer, anti-cancer, anti-radiation, anti-microbial and anti-pathogenic action.
  • Licorice (Glycyrrhizae Radix) is the same as or without the roots and cuticles of perennial herbaceous ( Glycyrrhiza uralensis ) and Glycyrrhiza glabra or other related plants of legumes (Leguminosae). 2007], roots are cut in autumn to remove stems, twigs and beard roots, cut to length and sun-dried.
  • the main pharmacological actions of licorice are known as a wide range of detoxification, antidiuresis, antitussive expectoration, anti-inflammatory, anti-allergic, anti-ulcer, and interpolation.
  • each of the shiho, rhubarb, and licorice are known to have anti-ulcer activity, they do not have sufficient effects to be used as a medicament for preventing or treating gastrointestinal diseases, and a composition for preventing or treating gastrointestinal diseases having better effects. Development is needed.
  • the present inventors recognized the necessity of developing a composition for the prevention or treatment of gastrointestinal diseases caused by mucosal damage of the stomach or duodenum, and studied the composition for the prevention or treatment of gastrointestinal diseases with superior effects.
  • the present invention has been found to have a significant gastrointestinal disease prevention and treatment effect when compared to the case of including a combination of two or more of, and licorice, each of which alone is unpredictable.
  • compositions for the prevention or treatment of effective gastrointestinal diseases comprising a combination of herbal medicines as an active ingredient.
  • Another object of the present invention to provide a pharmaceutical and health functional food comprising the composition for the prevention or treatment of gastrointestinal diseases.
  • compositions for the prevention or treatment of gastrointestinal diseases including two or more herbal drugs selected from the group consisting of Bupleuri Radix, Coptidis Rhizoma, and Glycyrrhizae Radix.
  • the present invention also provides a medicament comprising the composition and a pharmaceutically acceptable carrier or additive.
  • the present invention also provides a dietary supplement comprising the composition and a food acceptable carrier or additive.
  • composition for the prevention or treatment of gastrointestinal diseases according to the present invention is unpredictable to those skilled in the art in the prevention or treatment effect of gastrointestinal diseases as a result of combining two or more of Siho, rhubarb, and licorice, which are known to have an anti-ulcer effect. It turned out that there was remarkable effect of degree and was completed.
  • the present invention provides a composition for preventing or treating gastrointestinal diseases, including two or more herbal drugs selected from the group consisting of Buleuri Radix, Cooptidis Rhizoma, and Licorice (Glycyrrhizae Radix). .
  • Shiho, rhubarb, and licorice in the composition is not particularly limited in the combination ratio thereof, but may preferably comprise a ratio of 10-30 parts by weight of sulfur and 10-30 parts by weight of licorice with respect to 100 parts by weight of shiho. .
  • the herbal medicines constituting the composition of the present invention are obviously equivalent to those in the art, and include all the herbal medicines that can be used for the prevention or treatment of gastrointestinal diseases.
  • the shiho, rhubarb, and licorice each may be contained in the composition as a solvent extract of the herbal medicine, and may be contained in a pulverized product of the herbal medicine itself, a pulverized product of the dry herbal medicine, and the like, and the like.
  • Solvent extract of the herbal medicine may be extracted separately or together with each herbal medicine in water, an organic solvent, or a combination thereof, the organic solvent is C 1 -C 4 alcohol, acetone, chloroform, methylene chloride, ether, Ethyl acetate, hexane, or a combination thereof may be used, but is not limited thereto.
  • Examples of C 1 -C 4 alcohols include methanol, ethanol, propanol and butanol, and ethanol is most preferred.
  • the solvent extracts of shiho, rhubarb, and licorice may be prepared by any extraction method known to those skilled in the art of herbal extraction, but 10 to 80 at an extraction temperature of 10 ° C. to 80 ° C., preferably room temperature (25 ° C.). Using extraction methods such as hot water extraction, cold sediment extraction, reflux cooling extraction or ultrasonic extraction for 2 hours to 3 days, preferably, extraction may be carried out one to five times in succession by cold extraction. .
  • the solvent extract thus obtained can be obtained as a final extract by filtration under reduced pressure and the filtration extract is concentrated under reduced pressure at 20 to 100 ° C., preferably at room temperature (25 ° C.) with a rotary evaporator and lyophilized.
  • the composition comprising a combination of two or more of Siho, rhubarb, and licorice according to the present invention is effective in preventing or treating gastrointestinal diseases, and the gastrointestinal diseases include all gastrointestinal diseases known to be caused by mucosal damage of the stomach and twelve limbs. .
  • the gastrointestinal disease may be caused by various causes such as alcohol, smoking, stress, drugs, or a combination thereof, but is not limited thereto.
  • Drugs that cause the gastrointestinal disorders include, but are not limited to, nonsteroidal anti-inflammatory agents, steroids, and the like.
  • the nonsteroidal anti-inflammatory agents are typically indomethacin, diclofenac, aspirin, acetaminophen, ibuprofen, meloxycamp, naproxen and the like.
  • compositions according to the invention The prophylactic or therapeutic effect of such gastrointestinal diseases of the compositions according to the invention was demonstrated in the following examples. Specifically, as a result of administering to a rat a composition comprising a composition comprising a combination of two or more of sea lakes, yellow lotus, and licorice according to the present invention and causing gastric ulceration by alcohol, water restraint, or nonsteroidal anti-inflammatory drugs (NSAIDs), Compared to the non-administered group (control group) of the composition according to the present invention, the ulcer index of the stomach appeared to be significantly lower than that of the administration group.
  • NSAIDs nonsteroidal anti-inflammatory drugs
  • the preventive effect of after inducing direct ulceration of gastric tissue by acetic acid, a long term administration of a composition comprising a combination of two or more of sea tiger, yellow lotus, and licorice according to the present invention is followed by anti-ulcer action and mucosal regeneration effect by prostaglandins
  • the gastrointestinal disease treatment index was remarkably excellent in the administration group compared to the non-administration group (control group) of the composition according to the present invention, and showed a remarkably superior effect compared to the styrene tablet widely used as a conventional herbal medicine for treating gastrointestinal diseases. It has been confirmed that the therapeutic effect of gastrointestinal diseases has been demonstrated.
  • the respective doses are the same.
  • the composition comprising two or more herbal medicines according to the present invention when administered as compared to the case of administering each herbal extract alone, the effect of inhibiting gastric damage in rats is higher, thus preventing and treating gastrointestinal diseases. It has been proven to have synergistic action.
  • compositions according to the present invention in particular, the case comprising all three lakes, yellow lotus, and licorice, not only has synergism compared to the composition containing each lake, yellow lotus, or licorice alone, but also includes two herbal drugs. It was confirmed to have a synergistic effect compared with that. Furthermore, the composition according to the present invention contains herbal medicines that have been proven to be safe while being used for a very long time, and thus have little toxicity and side effects, and thus can be used safely for long-term treatment or for long-term treatment of gastrointestinal diseases.
  • the present invention provides a medicament comprising the composition according to the present invention, and a pharmaceutically acceptable carrier or additive.
  • the drug may be administered to various mammals including rats, mice, livestock, humans, etc. by various routes, for example oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or intracerebroventricular injections. May be administered.
  • the medicament may be formulated in conventional pharmaceutical formulations known in the art.
  • the medicament may be formulated and administered in any dosage form including, but not limited to, oral, injectable, suppository, transdermal, and non-administrative agents, but preferably liquids, suspensions, powders, granules, It may be formulated in oral dosage forms such as tablets, capsules, pills, emulsions, syrups, aerosols, or extracts.
  • each of the above formulations it may be prepared by the addition of a pharmaceutically acceptable carrier or additive necessary for the preparation of each formulation.
  • a pharmaceutically acceptable carrier or additive necessary for the preparation of each formulation.
  • one or more of a diluent, a lubricant, a binder, a disintegrant, a sweetener, a stabilizer, and a preservative may be used as the carrier, and as an additive, flavors, vitamins, and antioxidants may be used.
  • a diluent a lubricant, a binder, a disintegrant, a sweetener, a stabilizer, and a preservative
  • flavors, vitamins, and antioxidants may be used.
  • One or more types can be selected and used out of them.
  • the carrier and the additive may be any pharmaceutically acceptable, specifically, as a diluent, lactose, dextrose, sucrose, corn starch, soybean oil, microcrystalline cellulose, sorbitol, xylitol, or mannitol, magnesium stearate as a lubricant, As talc and a binder, polyvinylpyrrolidone or hydroxypropyl cellulose is preferable.
  • natural flavors such as plum flavor, lemon flavor, pineapple flavor, herbal flavor, natural pigments such as natural fruit juice, chlorophyllin, flavonoid, fructose, honey, sugar alcohol, sugar Sweetening ingredients such as, or may be used by mixing an acidulant such as citric acid, sodium citrate.
  • aqueous solutions there are sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories.
  • non-aqueous solvents and suspending agents propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate and the like can be used.
  • injectable esters such as ethyl oleate and the like
  • suppositories witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerol gelatin and the like can be used.
  • the drug can be appropriately added to or lowered the mixing ratio of the constituent herb appropriately within the range that effectively maintains the therapeutic or prophylactic effect of gastrointestinal diseases, 0.01-80% by weight of the herbal component constituting the composition according to the present invention, Preferably 1-50% by weight.
  • the pharmaceutical product may contain 0.01-10 g / kg / day, preferably 1-5 g / kg / day, based on the dry powder of the solvent extract. It may be administered once or several times a day, and may be appropriately increased or decreased depending on the age, sex, weight, diet, excretion rate, and other drugs currently being taken. Therefore, the pharmaceutical preparation according to the present invention is to be prepared in consideration of the range of effective amount, and the dosage unit formulation formulated in this way is a specialized dosage according to the judgment of experts and the needs of the individual to monitor or observe the administration of the drug as necessary It may be administered several times at intervals using a method or at regular intervals.
  • composition according to the present invention can also be used as a raw material of health functional food for the prevention or treatment of gastrointestinal diseases.
  • the present invention provides a dietary supplement comprising the composition according to the present invention, and a food acceptable carrier or additive.
  • Health functional foods defined in the present invention is a health function prescribed in the Food and Drug Administration Notice 2008-72 is sufficiently established that the newly defined functional and safety for the human body through the Act on Health Functional Foods amended in 2008 It means that it is a health functional food as listed in the regulations on the recognition of food functional ingredients.
  • Such dietary supplements can be formulated in the formulation of conventional dietary supplements known in the art.
  • the dietary supplement may be prepared, for example, as a powder, granules, tablets, pills, capsules, suspensions, emulsions, syrups, dips, liquids, extracts, gums, teas, jelly, or beverages.
  • any carrier or additive known to be usable in the art may be used to prepare a formulation to be prepared.
  • the dietary supplement may comprise 0.01 to 15% by weight, preferably 0.2 to 10% by weight of the total weight of the food ingredients constituting the composition according to the present invention, based on 100 mL when prepared as a beverage In the range of 0.1 to 30 g, preferably 0.2 to 5 g.
  • the beverage may further contain other ingredients in addition to the herbal ingredients, and may further contain various flavors or natural carbohydrates, etc. that are commonly used in beverages.
  • the natural carbohydrates include conventional sugars such as monosaccharides (eg, glucose, fructose, etc.), disaccharides (eg, maltose, sucrose, etc.), polysaccharides (eg, dextrin, cyclodextrin, etc.) and xylitol, sorbitol, erythritol, and the like.
  • Sugar alcohols may be contained.
  • the flavoring agent may contain natural flavoring agents (e.g., taumartin, stevia extract, etc.) and synthetic flavoring agents (e.g., saccharin, aspartame, etc.).
  • natural flavoring agents e.g., taumartin, stevia extract, etc.
  • synthetic flavoring agents e.g., saccharin, aspartame, etc.
  • the proportion of the natural carbohydrate is preferably contained in about 1 to 20 g, preferably about 5 to 12 g per 100 mL of beverage.
  • the drug and the health supplement according to the present invention may be administered simultaneously with two or more combinations of Shiho, rhubarb, and licorice, which are included as active ingredients, but the extent to which the composition can prevent or treat gastrointestinal diseases It may be administered sequentially at predetermined intervals within. If two or more combinations of shiho, rhubarb and licorice are to be administered at predetermined intervals, each active ingredient may be formulated in a separate, separate formulation. When two or more combinations of shiho, rhubarb, and licorice are to be administered simultaneously, they may be formulated in a uniformly mixed form in one formulation, or may be formulated in separate formulations and then administered simultaneously.
  • the composition according to the present invention comprises a combination of two or more of shiho, yellow lotus, and licorice, thereby having a remarkably effective effect in the treatment of gastrointestinal diseases associated with mucosal damage of the gastrointestinal or duodenal ulcer. It is preferable because it is composed of natural materials, so it has little toxicity to human body and little risk of recurrence. Therefore, the composition according to the present invention can be used as a medicine or health functional food for the prevention or treatment of various gastrointestinal diseases caused by alcohol, stress, smoking, or drugs.
  • FIG 1 and 2 are photographs of the herbal extract prepared according to one embodiment of the present invention to observe the inhibitory effect of gastric damage caused by diclofenac.
  • Figure 3 is a photograph of the herbal extract prepared according to an embodiment of the present invention to observe the effect of preventing gastric damage caused by indomethacin intraperitoneal administration through tissue staining.
  • Figure 4 is a photograph of the herbal extract prepared according to an embodiment of the present invention observed the effect of treating subacute gastric injury induced by acetic acid through tissue staining.
  • Ethanol causes bleeding and swelling of the submucosal muscle layer by direct stimulation of the gastric mucosa, causing temporary ischemia, causing necrosis of cells, reducing the amount of ATP in the mucosa and congestion of microcirculation.
  • Hydrochloric acid stimulates gastrointestinal motility, causing acute gastritis.
  • mice with no specific pathogen were purchased from the Charles River, followed by a week-long purifying period, and healthy rats weighing 270-280 g were used for the experiment.
  • Each group was divided into 5 animals, and each animal was orally administered at a dose of 100 mg / kg or 200 mg / kg to the fasted animal for 20 hours under free water intake and 150 mM after 1 hour.
  • 60% ethanol prepared with HCl solution was orally administered 1 mL per horse and gastric injury was induced for 1 hour.
  • the rats were sacrificed by suffocation with CO 2, and the stomach was extracted, fixed with 1% formalin solution, incised and extended along the Taiwanese area, and then visually observed gastrointestinal damage and the length of gastric ulceration index. Calculated.
  • a composite extract comprising each of the extracts of shiho, rhubarb and licorice prepared in Comparative Examples 1-3 and two herbal extracts of Example 1-3, and both shiho, rhubarb and licorice of Example 4 was prepared.
  • the test groups were compared for drug efficacy against alcoholic acute gastritis. Water was administered as a control and the experimental results are shown in Table 1 below.
  • Example 1 the administration of two or more complex extracts of shiho, rhubarb, and licorice as in Example 1-3 is significantly superior to the case of administration of a single extract of shiho, rhubarb and licorice respectively. It was found to have an anti-ulcer effect.
  • Example 4 the case of administering the composite extracts of Shiho, Huang lotus, and licorice, as in Example 4, as well as the case of administering a single extract of Shiho, Huang lotus and licorice, as well as two or more complex extracts It was found to have a remarkably good anti-ulcer effect.
  • the two or more herbal extracts of shiho, rhubarb, and licorice according to the present invention have a significant preventive effect against gastrointestinal diseases.
  • the herbal extract of Example 4 has a significantly better prevention of gastrointestinal diseases than styrene currently used for the treatment of gastrointestinal disorders against the gastric mucosa damaged by ethanol.
  • Example 4 As a test group, the herbal extract prepared in Example 4 was administered, and as a comparative example, styrene tablets (leaf extract 60 mg, Dong-A Pharmaceutical) were administered, and water was administered as a control to compare the drug efficacy.
  • styrene tablets leaf extract 60 mg, Dong-A Pharmaceutical
  • water was administered as a control to compare the drug efficacy.
  • the herbal extract of Example 4 has a significantly better prevention or treatment efficacy of gastrointestinal diseases, compared to the styrene tablets currently used for the treatment of gastrointestinal diseases, on gastric mucosa damaged by immersion restraint. It can be seen that.
  • Nonsteroidal anti-inflammatory agents inhibit the biosynthesis of prostaglandin (PG), leading to damage of the gastric mucosa.
  • PG prostaglandin
  • the preventive effect of gastric injury by diclofenac administration was confirmed.
  • Example 4 As a test group, the herbal extract prepared in Example 4 was administered, and as a comparative example, styrene tablets (leaf extract 60 mg, Dong-A Pharmaceutical) were administered, and water was administered as a control to compare drug efficacy.
  • styrene tablets leaf extract 60 mg, Dong-A Pharmaceutical
  • water was administered as a control to compare drug efficacy.
  • the herbal extract of Example 4 has a remarkably superior therapeutic effect compared to styrene tablets currently used as a gastrointestinal disease treatment for acute gastric mucosal damage caused by diclofenac.
  • the gastric wall damaged by diclofenac is inhibited by the administration of the herbal extract of Example 4 and Comparative Example 4 (styrene tablets), and the herbal extract of Example 4 is It has been confirmed that there is a concentration-dependent gastric damage inhibitory effect.
  • the drug was orally administered once daily for 6 days, followed by fasting for 24 hours, followed by intraperitoneal administration of indomethacin at a concentration of 70 mg / kg, and gastric injury for 7 hours.
  • the rats were sacrificed and their stomachs were extracted, fixed with 1% formalin solution, incised and extended along the Taiwanese area, and then the gastric ulcers were visually observed and the length of the gastric ulcer was measured and evaluated by gastric ulcer index.
  • Blood of test animals was collected and analyzed for the content of nitric oxide (NO), superoxide dismutase (SOD) and epidermal growth factor (EGF).
  • NO nitric oxide
  • SOD superoxide dismutase
  • EGF epidermal growth factor
  • Example 4 As a test group, the herbal extract prepared in Example 4 was administered, and as a comparative example, styrene tablets (leaf extract 60 mg, Dong-A Pharmaceutical) were administered, and water was administered as a control to compare drug efficacy.
  • styrene tablets leaf extract 60 mg, Dong-A Pharmaceutical
  • water was administered as a control to compare drug efficacy.
  • paraffin sections were prepared by fixing the tissue, stained, observed under a microscope, and photographed. The photograph is shown in FIG. 3.
  • the herbal extract of Example 4 has a significantly superior preventive effect compared to the styrene tablets currently used as a gastrointestinal disorder treatment against gastric mucosal damage caused by intraperitoneal indomethacin administration. have.
  • Example 4 As a test group, the herbal extract prepared in Example 4 was administered, and as a comparative example, styrene tablets (leaf extract 60 mg, Dong-A Pharmaceutical) were administered, and water was administered as a control to compare the drug efficacy.
  • styrene tablets leaf extract 60 mg, Dong-A Pharmaceutical
  • water was administered as a control to compare the drug efficacy.
  • paraffin sections were prepared by fixing the tissue, stained, observed under a microscope, and photographed. The photograph is shown in FIG. 4.
  • the herbal extract of Example 4 has an excellent therapeutic effect on the subtype of gastric mucosal damage caused by acetic acid.
  • gastric wall (B) damaged by acetic acid compared to normal group (A) was treated by administering the herbal extracts (E, F) and Comparative Example 1 (C, D) of Example 4. It can be confirmed that the herbal extract of Example 4 has a concentration-dependent gastric damage inhibitory effect.
  • Tablets for oral administration using the herbal extract prepared in Example 4 were prepared by granulation using wet granulation and dry granulation with the following composition, followed by tableting to prepare tablets.
  • Example 4 Using the herbal extract prepared in Example 4 to fill a gelatin capsule with the following composition to prepare a capsule.
  • Example 4 Using the herbal extract prepared in Example 4 to prepare a liquid formulation with the following composition.
  • Example 4 Using the herbal extract prepared in Example 4 was mixed in the following composition and filled in an airtight fabric to prepare a powder.
  • Water, walnut oil and vinegar may be used instead of honey.
  • the hot honey prepared as described above is kneaded by adding 5 g of the herbal extract prepared in Example 4, and then the dough is molded into a ring of equal size by using an artificial or a machine to prepare a pill.
  • the prepared pills are dried in a cool and dry place and then stored in a cool and airtight place.
  • a suspending agent is prepared according to a conventional method for preparing a suspending agent by mixing syrup, sugar, honey, or D-mannitol.
  • Chewing gum is prepared using a conventional method using the herbal extract prepared in Example 4 in the following composition and content.
  • Example 4 Using the herbal extract prepared in Example 4 to prepare a beverage using conventional methods in the following composition and content.
  • Example 4 Using the herbal extract prepared in Example 4 to prepare a candy using a conventional method with the following composition and content.
  • a mixture of 20% herbal extract and 80% crystalline lactitol is diluted with purified water and placed in a sauce pen.
  • the batch is first heated on a hot plate until all material is solubilized, then the batch is transferred to a vacuum cooker and further heated.
  • the formed blend forms a viscous mass even at relatively low temperatures.
  • the syrup is then transferred from the cooker to the thick plate and cured until a suitable tissue is formed for drop rolling. The cured mass is fed through a drop roller. Once imprinted, the candy has an acceptable quality.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La présente invention porte sur des compositions contenant deux médicaments à base d'herbe ou plus choisis dans un groupe constitué par Bupleuri Radix, Coptidis Rhizoma, et Glycyrrhizae Radix pour prévenir ou traiter des maladies gastro-intestinales, et porte sur des médicaments et des aliments de santé fonctionnels contenant les compositions. Les compositions selon la présente invention contiennent une combinaison de deux ou plus parmi Bupleuri Radix, Coptidis Rhizoma, et Glycyrrhizae Radix, pour présenter des effets remarquables, qui sont imprévisibles par l'homme du métier, dans le traitement de maladies gastro-intestinales liées à une lésion de la muqueuse provoquée par un ulcère à l'estomac ou un ulcère duodénal. Les compositions selon la présente invention sont souhaitables du fait qu'elles sont faites de matières naturelles de façon à ne causer aucune toxicité au corps humain et conduisent à peu de risque de récurrence de maladies. Par conséquent, les compositions selon la présente invention peuvent être utilisées en tant que médicaments ou aliments de santé fonctionnels pour prévenir ou traiter une pluralité de maladies gastro-intestinales provoquées par l'alcool, le stress, le tabac, les drogues ou similaires.
PCT/KR2010/001450 2009-03-13 2010-03-09 Compositions pour prévenir ou améliorer des maladies gastro-intestinales Ceased WO2010104309A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN2010800139052A CN102365091A (zh) 2009-03-13 2010-03-09 用于预防或改善胃肠道疾病的组合物
RU2011141504/15A RU2500416C2 (ru) 2009-03-13 2010-03-09 Композиции для предотвращения или облегчения желудочно-кишечных заболеваний
BRPI1009105A BRPI1009105A2 (pt) 2009-03-13 2010-03-09 composições para prevenir ou melhorar doenças gastrointestinais

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090021867A KR101099004B1 (ko) 2009-03-13 2009-03-13 위장질환의 예방 또는 개선용 조성물
KR10-2009-0021867 2009-03-13

Publications (3)

Publication Number Publication Date
WO2010104309A2 WO2010104309A2 (fr) 2010-09-16
WO2010104309A3 WO2010104309A3 (fr) 2011-01-06
WO2010104309A9 true WO2010104309A9 (fr) 2011-02-24

Family

ID=42728930

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2010/001450 Ceased WO2010104309A2 (fr) 2009-03-13 2010-03-09 Compositions pour prévenir ou améliorer des maladies gastro-intestinales

Country Status (7)

Country Link
KR (1) KR101099004B1 (fr)
CN (2) CN102365091A (fr)
BR (1) BRPI1009105A2 (fr)
MY (1) MY160409A (fr)
RU (1) RU2500416C2 (fr)
UA (1) UA99685C2 (fr)
WO (1) WO2010104309A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101263191B1 (ko) * 2010-05-06 2013-05-10 주식회사 사이그린 위장관 운동 장애 질환의 예방, 치료 또는 개선용 약학 조성물 및 건강기능식품용 조성물
CN102600284A (zh) * 2011-01-21 2012-07-25 李艳娜 一种治疗慢性结肠炎、直肠炎的中药灌肠剂
KR20110056459A (ko) * 2011-04-04 2011-05-30 정필구 치주질환의 예방 및 개선용 조성물
CN102631432B (zh) * 2012-05-10 2013-09-11 黄炳炎 一种防治亚健康的中药组合物
CN102697926B (zh) * 2012-06-12 2013-11-27 查迅 治疗溃疡性结肠炎的中药软膏及其制备方法
KR20140033998A (ko) * 2012-09-11 2014-03-19 씨제이제일제당 (주) 사이코사포닌 ａ, 베르베린 및 리코이소플라본 ｂ를 포함하는 위장질환의 예방 또는 치료용 조성물
CN103005063B (zh) * 2013-01-06 2014-02-12 江西省蚕桑茶叶研究所 一种金佛手袋泡茶
CN103223025A (zh) * 2013-05-21 2013-07-31 卫斌 一种治疗胃炎的药物及其制备方法
CN103432276B (zh) * 2013-09-16 2015-03-25 河北科技师范学院 治疗仔猪急性副伤寒的中草药口服液
CN104622989A (zh) * 2015-01-15 2015-05-20 西安医学院 一种中药复方灭菌剂及其制备方法
KR102634898B1 (ko) 2015-11-06 2024-02-08 주식회사 제뉴원사이언스 시호, 승마, 백작약 및 목향 혼합 추출물을 함유하는 염증성 장질환의 예방 및 치료용 약학 조성물
KR102434265B1 (ko) * 2017-09-20 2022-08-19 밍츄 리 위궤양 치료용 한방약
KR102428859B1 (ko) * 2020-05-29 2022-08-04 동성제약주식회사 안전성이 확보된 소화기계 질환 예방 또는 치료를 위한 경구투여용 약학 조성물
KR102786413B1 (ko) 2024-05-30 2025-03-26 조선대학교산학협력단 붉가시나무 추출물 또는 이의 분획물을 포함하는 위장 질환의 개선 또는 치료용 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1106678A (zh) * 1994-08-23 1995-08-16 路良宇 治疗胃肠炎、溃疡的药物和工艺
US6365198B1 (en) 2001-01-28 2002-04-02 Gulf Pharmaceutical Industries Pharmaceutical preparation for the treatment of gastrointestinal ulcers and hemorrhoids
AU2003225372A1 (en) * 2002-04-12 2003-10-27 Pangenomics Co., Ltd Crude drug composition for preventing and treating gastrointestinal dyskinetic diseases
CN1579485B (zh) * 2004-03-16 2010-04-28 南京师范大学 治疗肠功能紊乱的中药组合物及其制备方法
CN101209340B (zh) * 2006-12-25 2010-09-08 上海中医药大学附属岳阳中西医结合医院 治疗胃食管反流病的中药组合物
CN101342282B (zh) * 2007-07-11 2011-08-10 深圳市齐旺投资有限公司 一种治疗胃病的中药组合物及制备方法
CN100569263C (zh) * 2007-11-07 2009-12-16 北京中科雍和医药技术有限公司 一种治疗胃痛的药物组合物及其制备方法

Also Published As

Publication number Publication date
UA99685C2 (ru) 2012-09-10
WO2010104309A3 (fr) 2011-01-06
CN104248666A (zh) 2014-12-31
BRPI1009105A2 (pt) 2016-03-08
RU2011141504A (ru) 2013-04-20
CN102365091A (zh) 2012-02-29
RU2500416C2 (ru) 2013-12-10
KR101099004B1 (ko) 2011-12-28
WO2010104309A2 (fr) 2010-09-16
MY160409A (en) 2017-03-15
KR20100103305A (ko) 2010-09-27

Similar Documents

Publication Publication Date Title
WO2010104309A9 (fr) Compositions pour prévenir ou améliorer des maladies gastro-intestinales
WO2015190760A1 (fr) Composition pour la prévention et le traitement de la stéatose hépatique non alcoolique
WO2018174448A1 (fr) Composition pour le traitement et la prévention du syndrome climactérique contenant un extrait médicinal végétal combiné d'atractylis, de mori fructus, de lyciet commun, de longane, d'achyranthes, d'écorce d'eucommia et d'asperge de cochinchine merr. comme ingrédient actif, et son utilisation
WO2021091164A1 (fr) Composition pharmaceutique destinée à prévenir ou traiter l'obésité ou l'allergie comprenant un extrait de rose comme ingrédient actif
WO2016186349A2 (fr) Composition, contenant un extrait de quisaqualis indica, pour la prévention ou le traitement de l'hyperplasie prostatique
WO2011139118A2 (fr) Composition pharmaceutique et composition d'aliment naturel fonctionnel pour la prévention, le traitement ou l'amélioration de maladies de type dyskinésie gastro-intestinale
WO2020263010A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de la gastrite ou de l'ulcère gastroduodénal comprenant un complexe polysaccharide chargé négativement-anthocyanine en tant que principe actif
WO2014193114A1 (fr) Composition contenant des extraits phytothérapeutiques de pinellia et scutellaria pour réduire les effets secondaires dus aux médicaments anticancéreux
WO2014042426A1 (fr) Composition comprenant de la saikosaponine a, de la berbérine et de la licoisoflavone b pour la prévention ou le traitement de maladies gastriques
WO2017176001A1 (fr) Composition destinée à soulager les symptômes de la ménopause chez les femmes, contenant de l'extrait de sasa quelpaertensis nakai
WO2019124854A1 (fr) Composition pour prévenir ou traiter le syndrome de sécheresse oculaire, contenant un extrait mixte ou une fraction de celui-ci
WO2018131780A1 (fr) Composition destinée à prévenir ou à traiter la gastrite ou l'ulcère gastroduodénal
WO2021071269A1 (fr) Composition pour la prévention ou le traitement d'une maladie intestinale inflammatoire comprenant des extraits de plantes médicinales complexes
WO2013122344A1 (fr) Composition pharmaceutique contenant en tant qu'ingrédient actif un extrait provenant de l'écorce de liriodendron tulipifera
WO2013122345A1 (fr) Forme galénique améliorée contenant un extrait d'écorce de liriodendron tulipifera en tant qu'ingrédient actif
WO2017146486A1 (fr) Composition destinée à prévenir ou traiter l'hyperplasie bénigne de la prostate contenant de l'extrait de morus alba linnaeus
WO2012138076A2 (fr) Composition contenant un mélange d'extraits végétaux pour la prévention ou le traitement de maladies gastro-intestinales
WO2023167565A1 (fr) Composition pour prévenir, améliorer ou traiter des maladies parodontales
WO2014157811A1 (fr) Composition pour guérir ou traiter l'arthrite rhumatoïde et l'arthrose
WO2012105816A2 (fr) Composition destinée à prévenir et traiter le diabète et les complications du diabète comprenant une poudre d'amphicarpaea edgeworthii var. trisperma ou un extrait de celle-ci
WO2022139529A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de la gastrite ou de l'ulcère gastroduodénal comprenant un extrait de cinnamomum cassia, une fraction dudit extrait, un isolat de ladite fraction ou des composés isolés à partir de ladite fraction
WO2018190638A1 (fr) Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max
WO2023022244A1 (fr) Composition de protection du foie ou de prévention ou d'amélioration d'une maladie hépatique
WO2017111429A1 (fr) Composition pour le traitement du syndrome de sécheresse oculaire, contenant un extrait d'airelle noire en tant que substance active
WO2018038293A1 (fr) Composition pharmaceutique contenant un extrait de sophora japonica l. en tant que principe actif pour la prévention et le traitement de troubles neurodégénératifs

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080013905.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10751000

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 12011501823

Country of ref document: PH

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: A201112018

Country of ref document: UA

ENP Entry into the national phase

Ref document number: 2011141504

Country of ref document: RU

Kind code of ref document: A

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 23/11/2011)

122 Ep: pct application non-entry in european phase

Ref document number: 10751000

Country of ref document: EP

Kind code of ref document: A2

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: PI1009105

Country of ref document: BR

ENP Entry into the national phase

Ref document number: PI1009105

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20110913